read
interest
paper
obeid
et
al
inhibit
hepat
c
viru
replic
semisynthet
deriv
glycopeptid
antibiot
provid
us
possibl
explan
clinic
observ
made
would
like
report
elderli
patient
chronic
hepat
c
patient
alanin
aminotransferas
level
consist
ul
fibroscan
show
liver
stiff
kpa
correl
stage
iv
fibrosi
patient
complet
total
three
antivir
treatment
cycl
pegyl
interferon
weightbas
ribavirin
last
cours
therapi
maintain
week
finish
april
although
patient
experienc
ontreat
respons
relaps
occur
shortli
end
therapi
april
patient
receiv
right
hip
joint
replac
anoth
hospit
complic
delay
wound
heal
may
patient
fell
hip
repeat
surgeri
follow
day
fever
develop
june
two
blood
cultur
posit
staphylococcu
aureu
surgic
site
presum
focu
infect
antimicrobi
therapi
ampicillin
sulbactam
initi
patient
transfer
gastroenterolog
ward
hospit
june
consult
infecti
diseas
specialist
orthopaed
surgeon
decid
switch
antimicrobi
therapi
longterm
teicoplanin
start
juli
administ
mg
teicoplanin
intraven
two
three
time
week
total
week
trough
level
mgl
surprisingli
day
initi
teicoplanin
treatment
normal
serum
transaminas
level
measur
first
time
year
hepat
c
viral
load
measur
august
show
signific
decreas
patient
rna
load
log
iuml
previou
measur
june
log
iuml
subsequ
measur
yield
rna
load
iuml
august
log
iuml
septemb
last
day
teicoplanin
therapi
figur
transaminas
level
remain
normal
octob
elev
sinc
also
patient
hepat
c
rna
level
return
usual
baselin
level
log
iuml
evid
glycopeptid
deriv
show
antivir
effect
retrovirus
coronavirus
obeid
et
al
first
report
activ
teicoplanin
deriv
hepat
c
viru
replicon
vitro
model
mechan
action
compound
exact
molecular
substructur
respons
inhibit
viral
replic
yet
elucid
howev
author
specul
peptid
scaffold
common
substanc
might
play
major
role
antivir
activ
patient
show
signific
decreas
hepat
c
viral
load
transaminas
level
teicoplanin
therapi
teicoplanin
shown
enter
human
cell
therefor
postentri
interact
hepat
c
viru
replic
cycl
propos
obeid
et
al
compound
may
possibl
explan
observ
effect
anoth
conceiv
mechan
might
interfer
teicoplanin
host
cell
factor
lipid
metabol
membran
organ
import
hepat
c
viru
replic
suggest
heterolog
viral
infect
may
trigger
hepat
c
virusspecif
cell
respons
howev
hepat
b
viru
hiv
infect
exclud
patient
furthermor
patient
show
clinic
sign
influenza
influenza
activ
austria
time
absenc
explan
specul
teicoplanin
interf
hepat
c
viru
replic
led
observ
decreas
viral
load
unfortun
patient
avail
trial
repeat
exposur
teicoplanin
patient
current
undergo
treatment
tripl
antivir
therapi
best
knowledg
first
descript
possibl
effect
teicoplanin
vivo
hepat
c
viru
replic
studi
carri
part
routin
work
none
declar
sir
maraviroc
chemokin
coreceptor
antagonist
current
use
treatmentexperienc
patient
despit
fact
data
avail
new
antiretrovir
drug
infect
vitro
maraviroc
activ
recent
shown
howev
clinic
use
maraviroc
infect
